1. Home
  2. NTIP vs CGTX Comparison

NTIP vs CGTX Comparison

Compare NTIP & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTIP
  • CGTX
  • Stock Information
  • Founded
  • NTIP 1990
  • CGTX 2007
  • Country
  • NTIP United States
  • CGTX United States
  • Employees
  • NTIP N/A
  • CGTX N/A
  • Industry
  • NTIP Multi-Sector Companies
  • CGTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • NTIP Miscellaneous
  • CGTX Health Care
  • Exchange
  • NTIP Nasdaq
  • CGTX Nasdaq
  • Market Cap
  • NTIP 32.9M
  • CGTX 30.0M
  • IPO Year
  • NTIP 1998
  • CGTX 2021
  • Fundamental
  • Price
  • NTIP $1.38
  • CGTX $0.61
  • Analyst Decision
  • NTIP
  • CGTX Strong Buy
  • Analyst Count
  • NTIP 0
  • CGTX 6
  • Target Price
  • NTIP N/A
  • CGTX $8.30
  • AVG Volume (30 Days)
  • NTIP 12.1K
  • CGTX 857.7K
  • Earning Date
  • NTIP 03-07-2025
  • CGTX 03-25-2025
  • Dividend Yield
  • NTIP 7.30%
  • CGTX N/A
  • EPS Growth
  • NTIP N/A
  • CGTX N/A
  • EPS
  • NTIP N/A
  • CGTX N/A
  • Revenue
  • NTIP $1,881,000.00
  • CGTX N/A
  • Revenue This Year
  • NTIP N/A
  • CGTX N/A
  • Revenue Next Year
  • NTIP N/A
  • CGTX N/A
  • P/E Ratio
  • NTIP N/A
  • CGTX N/A
  • Revenue Growth
  • NTIP 129.39
  • CGTX N/A
  • 52 Week Low
  • NTIP $1.22
  • CGTX $0.34
  • 52 Week High
  • NTIP $2.25
  • CGTX $2.95
  • Technical
  • Relative Strength Index (RSI)
  • NTIP 52.63
  • CGTX 41.75
  • Support Level
  • NTIP $1.35
  • CGTX $0.60
  • Resistance Level
  • NTIP $1.41
  • CGTX $0.68
  • Average True Range (ATR)
  • NTIP 0.03
  • CGTX 0.06
  • MACD
  • NTIP -0.00
  • CGTX -0.02
  • Stochastic Oscillator
  • NTIP 60.00
  • CGTX 15.00

About NTIP Network-1 Technologies Inc.

Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property rights. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Share on Social Networks: